Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study

Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study

Background & aims: The CFTR-modulating therapy Elexaftor – Tezacaftor - Ivacaftor (ETI) has been widely prescribed since its approval in 2020 in the European Union. The aim of this study was to methodically evaluate the effects of an ETI treatment on clinical, biochemical data and Pseudomona...

Full description

Bibliographic Details
Main Authors: Alexander Schnell, Hannah Hober, Natalie Kaiser, Renate Ruppel, Annika Geppert, Christina Tremel, Julia Sobel, Erika Plattner, Joachim Woelfle, André Hoerning
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Heliyon
Subjects:
Cystic fibrosis
CFTR modulator
Clinical data
Inflammation markers
Elexacaftor
Tezacaftor
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023029638

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023029638

Similar Items